Skip to main content

Table 3 Receptor biomarkers identified in the literature search (with some selected references)

From: Sepsis biomarkers: a review

Sepsis marker

Evaluated in experimental studies

Evaluated in clinical studies

Evaluated as a prognostic factor

Comment

CC chemokine receptor (CCR) 2 [95]

√

   

CCR 3 [96]

 

C

√

Distinguished between survivors and non-survivors at 28 days

C5L2 [97]

√

B

√

Predicted development of MOF

CRTh2 [98]

 

C

√

Distinguished between survivors and non-survivors at 28 days

Fas receptor (soluble) [99]

 

B(m)

√

Predicted development of MOF

Fc-gamma RIII [100]

 

A

√

Increased in sepsis compared with healthy controls, correlated with APACHE II score

FLT-1 (soluble) [101, 102]

√

C

√

Correlated with APACHE II score

GP130 [103]

 

A

 

Increased in sepsis compared with healthy controls

IL-2 receptor (soluble) [104]

 

C

√

Predicted development of septic shock

Group II phospholipase A2 (PLA2-II) (soluble) [105, 106]

√

B

 

Distinguished between survivors and non-survivors at 28 days

RAGE (soluble) [107]

 

B

√*

Distinguished between survivors and non-survivors at 28 days

ST2 (soluble, IL-1 receptor) [108]

 

A(s)

√

Increased in sepsis compared with healthy controls

Toll-like receptor (TLR) 2 and 4 [109]

√

B

√

Increased in septic compared with non-septic critically ill patients

Transient receptor potential vanilloid (TRPV)1 [110]

√

   

TREM-1 (soluble) [111, 112]

√

C

√

Distinguished between survivors and non-survivors at 28 days

TNF-receptor (soluble) [113]

 

B

 

Predicted development of MOF

Urokinase type plasminogen activator receptor (uPAR) (soluble) [114]

 

C(m)

√

Distinguished between survivors and non-survivors at 28 days

  1. *sensitivity and specificity of less than 90%; A, Clinical study with less than 20 patients; B, Clinical study with 20 to 50 patients; C, Clinical study with more than 50 patients; (s), surgical patients only; (m), medical patients only.
  2. APACHE: acute physiology and chronic health evaluation; MOF: multiple organ failure; TREM: triggering receptor expressed on myeloid cells; RAGE: receptor for advanced glycation end-products.